Market Overview

Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting

Share:





Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing botulinum toxin products for use in aesthetic and therapeutic
indications, today announced presentation of clinical data from the
company's BELMONT Phase 2 study of DaxibotulinumtoxinA Injectable
(RT002) at the 2017 American Academy of Dermatology (AAD) Annual
Meeting, taking place at the Orange County Convention Center in Orlando,
Florida, March 3-7, 2017. BELMONT was the company's Phase 2 active
comparator, placebo-controlled, multi-center study to evaluate the
safety, efficacy, and duration of effect of RT002 injectable for the
treatment of glabellar (frown) lines, the 24-week results of which were
reported in October 2015. Findings from a patient's perspective study
also being reported at the AAD annual meeting confirm the content
validity of patient questionnaires in measuring the impact of frown
lines.

Scheduled data presentations at 2017 AAD Annual Meeting:

Poster Presentation: "Duration and Onset of Glabellar Frown Line
Reduction after an Injection of DaxibotulinumtoxinA: Results of the
BELMONT Study", March 3, 1:30 PM to 1:35 PM ET, Orlando, Florida

A poster highlights final data from the BELMONT Phase 2 active
comparator and placebo-controlled study of RT002 injectable for the
treatment of moderate to severe glabellar lines in adults.

Poster Presentation: "Impacts of Glabellar Facial Lines – A
Patient Perspective", March 3, 2:15 PM to 2:20 PM ET, Orlando, Florida

A second poster reports on findings validating the Patient Frown Wrinkle
Severity (PFWS) assessment, currently being used in Revance's SAKURA
Phase 3 clinical program, and two recently developed questionnaires, the
Frown Line Impact Scale (FLIS) and the Facial Age Self Evaluation (FASE)
scale.

"Physician interest continues to mount for our BELMONT results, and AAD
provides an important opportunity to showcase our differentiated
clinical findings, including increased response rates and extended
duration of effect of RT002 compared to the market-leading neurotoxin,"
said Dan Browne, President and Chief Executive Officer at Revance. "A
content validity study also examines our innovation of clinical
assessment tools, further underscoring our commitment to delineate the
patient experience and outcomes."

About Revance Therapeutics, Inc.

Revance, a Silicon Valley-based biotechnology company, is committed to
the advancement of remarkable science. The company is developing a
portfolio of products for aesthetic medicine and underserved therapeutic
specialties, including dermatology, orthopedics and neurology. Revance's
science is based upon a proprietary peptide technology, which when
combined with active drug molecules, may help address current unmet
needs. Revance's initial focus is on developing daxibotulinumtoxinA, the
company's highly purified botulinum toxin, for a broad spectrum of
aesthetic and therapeutic indications, including facial wrinkles and
muscle movement disorders.

The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis with the potential to be
the first long-acting neuromodulator. The company holds worldwide rights
for all indications of RT002 injectable and RT001 topical and the
pharmaceutical uses of its proprietary peptide technology platform. More
information on Revance may be found at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks
of Revance Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including
statements related to the process and timing of, and ability to
complete, current and anticipated future clinical development of our
investigational drug product candidates, including but not limited to
initiation and design of clinical studies for current and future
indications, related results and reporting of such results; statements
about our business strategy, timeline and other goals and market for our
anticipated products, plans and prospects; and statements about our
ability to obtain regulatory approval; and potential benefits of our
drug product candidates and our technologies.

Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from our
expectations. These risks and uncertainties include, but are not limited
to: the outcome, cost, and timing of our product development activities
and clinical trials; the uncertain clinical development process,
including the risks that interim results are not indicative of final
results and that clinical trials may not have an effective design or
generate positive results; our ability to obtain and maintain regulatory
approval of our drug product candidates; our ability to obtain funding
for our operations; our plans to research, develop, and commercialize
our drug product candidates; our ability to achieve market acceptance of
our drug product candidates; unanticipated costs or delays in research,
development, and commercialization efforts; the applicability of
clinical study results to actual outcomes; the size and growth potential
of the markets for our drug product candidates; our ability to
successfully commercialize our drug product candidates and the timing of
commercialization activities; the rate and degree of market acceptance
of our drug product candidates; our ability to develop sales and
marketing capabilities; the accuracy of our estimates regarding
expenses, future revenues, capital requirements and needs for financing;
our ability to continue obtaining and maintaining intellectual property
protection for our drug product candidates; and other risks. Detailed
information regarding factors that may cause actual results to differ
materially from the results expressed or implied by statements in this
press release may be found in Revance's periodic filings with the
Securities and Exchange Commission (the "SEC"), including factors
described in the section entitled "Risk Factors" of our annual report on
Form 10-K filed February 28, 2017. These forward-looking statements
speak only as of the date hereof. Revance disclaims any obligation to
update these forward-looking statements.

View Comments and Join the Discussion!